Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:01:50 2025-07-15 EDT			5-day change	1st Jan Change
442.90 ^DKK	-0.08%		-1.34%	-28.88%

05:22am	Indutrade: Life Science Achieved Positive Organic Growth Excluding Novo Nordisk Sales	FW
04:27am	NOVO NORDISK : Berenberg sticks Neutral	ZD

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year

Published on 2025-06-12 at 13:34, updated on 2025-06-12 at 14:14

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Indutrade: Life Science Achieved Positive Organic Growth Excluding Novo Nordisk Sales	05:22am	FW
NOVO NORDISK : Berenberg sticks Neutral	04:27am	ZD
Carnegie Strategy Fund Down 0.44% in June — New Investments in Novo Nordisk and SKF	07-14	FW
Clever Culture Says Novo Nordisk to Assess Its APAS Technology for Use Across Manufacturing Network	07-14	MT
Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	07-13	RE
European stocks down with bank and healthcare drag, US-EU tariffs in focus	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
NOVO NORDISK : Gets a Buy rating from UBS	07-11	ZD
Wall Street Waits to Hear the Numbers	07-11
Mining, healthcare prop up European shares; US-EU trade talks in focus	07-10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
European shares close at four-week high on banks boost; US trade talks in focus	07-09	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	07-09	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	07-09	ZD
Europe rises despite new US tariff mayhem	07-09	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	07-08	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	07-08	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	07-08	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	07-08	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company